Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
This grant supports planning of cancer prevention and control clinical trials to enhance trial design, feasibility, and reduce costs for effective cancer interventions.
Browse similar grants
Funder: National Institutes of Health
Due Dates: February 25, 2027 (Application) | June 25, 2027 (Application) | October 25, 2027 (Application)
Funding Amounts: Up to $225,000 annually in direct costs; $450,000 total without a clinical trial or $600,000 with a pilot/feasibility trial, over up to three years
Summary: NCI supports planning studies that resolve critical information gaps before a full-scale, multicenter Phase II or later cancer prevention and control trial.
Key Information: Preliminary efficacy or effectiveness data supporting the future intervention trial must already exist when applying.
Description
The National Cancer Institute (NCI), part of NIH, uses this R34 program to support studies that acquire data needed to complete a future multicenter Phase II or later clinical trial protocol. Its scope spans cancer prevention and interception, screening, early detection, cancer-related health behaviors, implementation science, healthcare delivery, survivorship, supportive and palliative care, symptom management, and quality of life.
Planning studies should resolve uncertainties about populations, recruitment, interventions, endpoints, statistical design, or operational feasibility. Supported activities can include refining outcome instruments, testing accrual strategies, standardizing interventions across sites, and assessing acceptability or adherence. A pilot/feasibility clinical trial is optional and should be included only when essential. The goal is to produce scientifically necessary information sufficient to decide whether—and how—the future trial should proceed, rather than establish its initial efficacy rationale.
